Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Healthcare Industry News How camptothecin from the cancer tree is changing cancer treatment with DNA-targeted therapy Learn how camptothecin, a natural compound from Camptotheca acuminata, is transforming cancer therapy through DNA topoisomerase I inhibition and drug innovation. bypharmanewsdailyJuly 12, 2025